Low-dose estrogen and drospirenone combination: Effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women

Fertility and Sterility

Volumn 95, Issue 1, 2011, Pages 158-163

  Villa, Paola ^a   Suriano, Rosanna ^a   Ricciardi, Luigi ^a   Tagliaferri, Valeria ^a   De Cicco, Simona ^a   De Franciscis, Pasquale ^b   Colacurci, Nicola ^b   Lanzone, Antonio ^a,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

cardiovascular disease; Drospirenone; insulin metabolism; menopause

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; DROSPIRENONE; ESTROGEN; FATTY ACID; GLYCOGEN; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLYCOGEN METABOLISM; HUMAN; HUMAN EXPERIMENT; INSULIN METABOLISM; LOW DRUG DOSE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ANDROSTENES; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ENERGY METABOLISM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MIDDLE AGED; PLACEBO EFFECT; POSTMENOPAUSE; RISK FACTORS; VASODILATION;

EID: 78650417607     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2010.07.001     Document Type: Article

References (33)

1. North American Menopause Society Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society Menopause 17 2010 242 255
2. K. Peeyananjarassri, and R. Baber Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials Climacteric 8 2005 13 23
3. A. Wakatsuki, Y. Okatani, N. Ikenoue, K. Shinohara, K. Watanabe, and T. Fukaya Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women Circulation 108 2003 808 813
4. G. Mercuro, C. Vitale, M. Fini, S. Zoncu, F. Leonardo, and G.M. Rosano Lipid profiles and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial Int J Cardiol 89 2003 257 265
5. R.A. Lobo, T. Bush, B.R. Carr, and J.H. Pickar Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism Fertil Steril 76 2001 13 24
6. C. Li, G. Samsioe, C. Borgfeldt, P.O. Bendahl, K. Wilawan, and A. Aberg Low-dose hormone therapy and carbohydrate metabolism Fertil Steril 79 2003 550 555
7. P. Villa, F. Sagnella, C. Perri, R. Suriano, L. Ricciardi, and A. Lanzone Low- and standard-estrogen dosage in oral therapy: dose-dependent effects on insulin and lipid metabolism in healthy postmenopausal women Climacteric 11 2008 498 508
8. M. Sanada, Y. Higashi, K. Nakagawa, M. Tsuda, I. Kodama, and M. Kimura A comparison of low-dose and standard-dose oral estrogen on forearm endothelial function in early postmenopausal women J Clin Endocrinol Metab 88 2003 1303 1309
9. G.M. Rosano, C. Vitale, G. Marazzi, and M. Volterrani Menopause and cardiovascular disease: the evidence Climacteric 10 Suppl 1 2007 19 24
10. H.N. Hodis, W.J. Mack, R.A. Lobo, D. Shoupe, A. Sevanian, and P.R. Mahrer Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial Ann Intern Med 135 2001 939 953
11. P. Angerer, S. Störk, W. Kothny, P. Schmitt, and C. von Schacky Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial Arterioscler Thromb Vasc Biol 21 2001 262 268
12. W.B. White, V. Hanes, V. Chauhan, and B. Pitt Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension Hypertension 48 2006 246 253
13. C. Battaglia, A. Cianciosi, F. Mancini, N. Persico, G. Sisti, and F. Facchinetti Angeliq versus Activelle in normotensive postmenopausal women: a prospective, randomized pilot study Menopause 16 2009 803 809
14. R.A. DeFronzo, J.D. Tobin, and R. Andres Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol Gastrointest Liver Physiol 237 1979 G214 G223
15. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
16. J.C. Levy, D.R. Matthews, and M.P. Hermans Correct homeostasis model assessment (HOMA) evaluation uses the computer program Diabetes Care 21 1998 2191 2192
17. E.J. Benjamin, M.G. Larson, M.J. Keyes, G.F. Mitchell, R.S. Vasan, and J.F. Keaney Jr. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study Circulation 109 2004 613 619
18. M.C. Corretti, T.J. Anderson, E.J. Benjamin, D. Celermajer, F. Charbonneau, and M.A. Creager Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force J Am Coll Cardiol 39 2002 257 265
19. S. Kwok, P.L. Selby, P. McElduff, I. Laing, B. Mackness, and M.I. Mackness Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy Clin Endocrinol 61 2004 760 767
20. D.F. Archer Drospirenone and estradiol: a new option for the postmenopausal woman Climacteric 10 Suppl 1 2007 3 10
21. I.F. Godsland The influence of female sex steroids on glucose metabolism and insulin action J Intern Med Suppl 738 1996 1 60
22. S. Lello, G. Primavera, L. Colonna, G. Vittori, F. Guardianelli, and R. Sorge Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations Gynecol Endocrinol 24 2008 718 723
23. U. Fuhrmann, R. Krattenmacher, E.P. Slater, and K.H. Fritzemeier The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential Contraception 54 1996 243 251
24. J.M. Foidart, and T. Faustmann Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen Gynecol Endocrinol 23 2007 692 699
25. L.P. Shulman A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone J Womens Health 15 2006 584 590
26. R.A. Preston Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women Climacteric 12 Suppl 1 2009 66 70
27. J.F. Arnal, H. Laurell, C. Fontaine, A. Billon, B. Calippe, and F. Lenfant Estrogen receptor actions on vascular biology and inflammation: implications in vascular pathophysiology Climacteric 12 Suppl 1 2009 12 17
28. A.O. Mueck, and H. Seeger Biochemical markers surrogating on vascular effects of sex steroid hormones Gynecol Endocrinol 22 2006 163 173
29. C. Vitale, G. Mercuro, E. Cerquetani, G. Marazzi, R. Patrizi, and F. Pelliccia Time since menopause influences the acute and chronic effect of estrogens on endothelial function Arterioscler Thromb Vasc Biol 28 2008 348 352
30. C. Vitale, M. Fini, F. Leonardo, P. Rossini, E. Cerquetani, and G.M. Rosano Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease Maturitas 14 40 2001 239 245
31. M. Zerr-Fouineau, M. Jourdain, C. Boesch, M. Hecker, C. Bronner, and V.B. Schini-Kerth Certain progestins prevent the enhancing effect of 17beta-estradiol on NO-mediated inhibition of platelet aggregation by endothelial cells Arterioscler Thromb Vasc Biol 29 2009 586 593
32. T. Simoncini, X.D. Fu, A. Caruso, S. Garibaldi, C. Baldacci, and A.R. Genazzani Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors Hum Reprod 22 2007 2325 2334
33. J. Knuuti, R. Kalliokoski, T. Janatuinen, J. Hannukainen, K.K. Kalliokoski, and J. Koskenvuo Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris Am J Cardiol 99 2007 1648 1652